@article{aalen1978empirical,
  title={An empirical transition matrix for non-homogeneous Markov chains based on censored observations},
  author={Aalen, Odd O and Johansen, S{\o}ren},
  journal={Scandinavian Journal of Statistics},
  pages={141--150},
  year={1978},
  publisher={JSTOR}
}

@article{baio2015probabilistic,
  title={Probabilistic sensitivity analysis in health economics},
  author={Baio, Gianluca and Dawid, A Philip},
  journal={Statistical methods in medical research},
  volume={24},
  number={6},
  pages={615--634},
  year={2015},
  publisher={SAGE Publications Sage UK: London, England}
}

@article{barton2008optimal,
  title={Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI)},
  author={Barton, Garry R and Briggs, Andrew H and Fenwick, Elisabeth AL},
  journal={Value in Health},
  volume={11},
  number={5},
  pages={886--897},
  year={2008},
  publisher={Wiley Online Library}
}

@article{bilir2016economic,
  title={Economic burden of toxicities associated with treating metastatic melanoma in the United States},
  author={Bilir, S Pinar and Ma, Qiufei and Zhao, Zhongyun and Wehler, Elizabeth and Munakata, Julie and Barber, Beth},
  journal={American health \& drug benefits},
  volume={9},
  number={4},
  pages={203},
  year={2016},
  publisher={Engage Healthcare Communications, LLC}
}

@article{black1990plane,
  title={The CE plane: a graphic representation of cost-effectiveness},
  author={Black, William C},
  journal={Medical decision making},
  volume={10},
  number={3},
  pages={212--214},
  year={1990},
  publisher={Sage Publications Sage CA: Thousand Oaks, CA}
}

@article{briggs1999bayesian,
  title={A Bayesian approach to stochastic cost-effectiveness analysis},
  author={Briggs, Andrew H},
  journal={Health Economics},
  volume={8},
  number={3},
  pages={257--261},
  year={1999},
  publisher={Wiley Online Library}
}

@article{cetin2011survival,
  title={Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program},
  author={Cetin, Karynsa and Ettinger, David S and Hei, Yong-jiang and D O'Malley, Cynthia},
  journal={Clinical epidemiology},
  volume={3},
  pages={139},
  year={2011},
  publisher={Dove Press}
}

@article{claxton2005probabilistic,
  title={Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra},
  author={Claxton, Karl and Sculpher, Mark and McCabe, Chris and Briggs, Andrew and Akehurst, Ron and Buxton, Martin and Brazier, John and O'Hagan, Tony},
  journal={Health economics},
  volume={14},
  number={4},
  pages={339--347},
  year={2005},
  publisher={Wiley Online Library}
}

@article{d2010metastatic,
  title={Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up},
  author={D'addario, G and Fr{\"u}h, M and Reck, M and Baumann, P and Klepetko, W and Felip, EESMO and ESMO Guidelines Working Group},
  journal={Annals of oncology},
  volume={21},
  number={suppl\_5},
  pages={v116--v119},
  year={2010},
  publisher={Oxford University Press}
}

@article{de2011mstate,
  title={mstate: an R package for the analysis of competing risks and multi-state models},
  author={de Wreede, Liesbeth C and Fiocco, Marta and Putter, Hein and others},
  journal={Journal of Statistical Software},
  volume={38},
  number={7},
  pages={1--30},
  year={2011}
}

@book{dias2018network,
  title={Network meta-analysis for decision-making},
  author={Dias, Sofia and Ades, AE and Welton, Nicky J and Jansen, Jeroen P and Sutton, Alexander J},
  year={2018},
  publisher={John Wiley \& Sons}
}

@article{doyle2008health,
  title={Health state utility scores in advanced non-small cell lung cancer},
  author={Doyle, Scott and Lloyd, Andrew and Walker, Mel},
  journal={Lung Cancer},
  volume={62},
  number={3},
  pages={374--380},
  year={2008},
  publisher={Elsevier}
}

@article{fenwick2001representing,
  title={Representing uncertainty: the role of cost-effectiveness acceptability curves},
  author={Fenwick, Elisabeth and Claxton, Karl and Sculpher, Mark},
  journal={Health economics},
  volume={10},
  number={8},
  pages={779--787},
  year={2001},
  publisher={Wiley Online Library}
}

@article{garrison2017toward,
  title={Toward a broader concept of value: identifying and defining elements for an expanded cost-effectiveness analysis},
  author={Garrison, Louis P and Kamal-Bahl, Sachin and Towse, Adrian},
  journal={Value in Health},
  volume={20},
  number={2},
  pages={213--216},
  year={2017},
  publisher={Elsevier}
}

@article{graham2018budget,
  title={Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a US Health Plan},
  author={Graham, Jonathan and Earnshaw, Stephanie and Burslem, Kate and Lim, Jonathan},
  journal={Journal of Managed Care \& Specialty Pharmacy},
  volume={24},
  number={6},
  pages={544--553},
  year={2018},
  publisher={Academy of Managed Care Pharmacy}
}

@article{hanly2012breast,
  title={Breast and prostate cancer productivity costs: a comparison of the human capital approach and the friction cost approach},
  author={Hanly, Paul and Timmons, Aileen and Walsh, Paul M and Sharp, Linda},
  journal={Value in health},
  volume={15},
  number={3},
  pages={429--436},
  year={2012},
  publisher={Elsevier}
}

@article{hoeting1999bayesian,
  title={Bayesian model averaging: a tutorial},
  author={Hoeting, Jennifer A and Madigan, David and Raftery, Adrian E and Volinsky, Chris T},
  journal={Statistical science},
  pages={382--401},
  year={1999},
  publisher={JSTOR}
}

@misc{noone2018seer,
  title={{SEER} Cancer Statistics Review, 1975-2015},
  author={Noone, AM and Howlader, N and Krapcho, M and Miller, D and Brest, A and Yu, M and Ruhl. J and Tatalovich, Z and
   Mariotto, A and Lewis, DR and Chen, HS and Feuer, EJ and Cronin, KA},
  howpublished = {National Cancer Institute. Bethesda, MD, \url{https://seer.cancer.gov/csr/1975_2015/}},
  note = {based on November 2017 SEER data submission, posted to the SEER web site, April 2018}
}

@article{jackson2016flexsurv,
  title={flexsurv: a platform for parametric survival modeling in R},
  author={Jackson, Christopher H},
  journal={Journal of Statistical Software},
  volume={70},
  year={2016},
  publisher={Europe PMC Funders}
}

@article{jansen2014indirect,
  title={Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report},
  author={Jansen, Jeroen P and Trikalinos, Thomas and Cappelleri, Joseph C and Daw, Jessica and Andes, Sherry and Eldessouki, Randa and Salanti, Georgia},
  journal={Value in Health},
  volume={17},
  number={2},
  pages={157--173},
  year={2014},
  publisher={Elsevier}
}

@article{jansen2012directed,
  title={Directed acyclic graphs can help understand bias in indirect and mixed treatment comparisons},
  author={Jansen, Jeroen P and Schmid, Christopher H and Salanti, Georgia},
  journal={Journal of clinical epidemiology},
  volume={65},
  number={7},
  pages={798--807},
  year={2012},
  publisher={Elsevier}
}

@article{jansen2013network,
  title={Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers},
  author={Jansen, Jeroen P and Naci, Huseyin},
  journal={BMC medicine},
  volume={11},
  number={1},
  pages={159},
  year={2013},
  publisher={BioMed Central}
}

@article{jansen2013multivariate,
  title={Multivariate Network Meta-Analysis of Progression Free Survival and Overall Survival},
  author={Jansen, JP and Trikalinos, T},
  journal={Value in Health},
  volume={16},
  number={7},
  pages={A617},
  year={2013},
  publisher={Elsevier}
}

@article{jemal2011global,
  title={Global cancer statistics},
  author={Jemal, Ahmedin and Bray, Freddie and Center, Melissa M and Ferlay, Jacques and Ward, Elizabeth and Forman, David},
  journal={CA: a cancer journal for clinicians},
  volume={61},
  number={2},
  pages={69--90},
  year={2011},
  publisher={Wiley Online Library}
}


@book{keeney1993decisions,
  title={Decisions with multiple objectives: preferences and value trade-offs},
  author={Keeney, Ralph L and Raiffa, Howard},
  year={1993},
  publisher={Cambridge university press}
}


@article{lakdawalla2017insurance,
  title={The insurance value of medical innovation},
  author={Lakdawalla, Darius and Malani, Anup and Reif, Julian},
  journal={Journal of public economics},
  volume={145},
  pages={94--102},
  year={2017},
  publisher={Elsevier}
}

@article{latremouille2017economic,
  title={The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States},
  author={Latremouille-Viau, Dominick and Chang, Jane and Guerin, Annie and Shi, Sherry and Wang, Ed and Yu, Justin and Ngai, Christopher},
  journal={Journal of medical economics},
  volume={20},
  number={1},
  pages={54--62},
  year={2017},
  publisher={Taylor \& Francis}
}

@article{lynch2004activating,
  title={Activating mutations in the epidermal growth factor receptor underlying responsiveness of non--small-cell lung cancer to gefitinib},
  author={Lynch, Thomas J and Bell, Daphne W and Sordella, Raffaella and Gurubhagavatula, Sarada and Okimoto, Ross A and Brannigan, Brian W and Harris, Patricia L and Haserlat, Sara M and Supko, Jeffrey G and Haluska, Frank G and others},
  journal={New England Journal of Medicine},
  volume={350},
  number={21},
  pages={2129--2139},
  year={2004},
  publisher={Mass Medical Soc}
}

@article{ma2011t790m,
  title={{T790M} and acquired resistance of {EGFR} {TKI}: a literature review of clinical reports},
  author={Ma, Chunyan and Wei, Shuzhen and Song, Yong},
  journal={Journal of thoracic disease},
  volume={3},
  number={1},
  pages={10},
  year={2011},
  publisher={AME Publications}
}

@article{mehnert2011employment,
  title={Employment and work-related issues in cancer survivors},
  author={Mehnert, Anja},
  journal={Critical Reviews in Oncology/Hematology},
  volume={77},
  number={2},
  pages={109--130},
  year={2011},
  publisher={Elsevier}
}

@article{nafees2008health,
  title={Health state utilities for non small cell lung cancer},
  author={Nafees, Beenish and Stafford, Megan and Gavriel, Sonia and Bhalla, Shkun and Watkins, Jessamy},
  journal={Health and quality of life outcomes},
  volume={6},
  number={1},
  pages={84},
  year={2008},
  publisher={BioMed Central}
}

@article{nafees2017health,
  title={Health state utilities in non--small cell lung cancer: An international study},
  author={Nafees, Beenish and Lloyd, Andrew J and Dewilde, Sarah and Rajan, Narayan and Lorenzo, Maria},
  journal={Asia-Pacific Journal of Clinical Oncology},
  volume={13},
  number={5},
  pages={e195--e203},
  year={2017},
  publisher={Wiley Online Library}
}

@article{putter2007tutorial,
  title={Tutorial in biostatistics: competing risks and multi-state models},
  author={Putter, Hein and Fiocco, Marta and Geskus, Ronald B},
  journal={Statistics in medicine},
  volume={26},
  number={11},
  pages={2389--2430},
  year={2007},
  publisher={Wiley Online Library}
}

@article{sanders2016recommendations,
  title={Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine},
  author={Sanders, Gillian D and Neumann, Peter J and Basu, Anirban and Brock, Dan W and Feeny, David and Krahn, Murray and Kuntz, Karen M and Meltzer, David O and Owens, Douglas K and Prosser, Lisa A and others},
  journal={Jama},
  volume={316},
  number={10},
  pages={1093--1103},
  year={2016},
  publisher={American Medical Association}
}

@article{shafrin2017patient,
  title={Patient versus physician valuation of durable survival gains: implications for value framework assessments},
  author={Shafrin, Jason and Schwartz, Taylor T and Okoro, Tony and Romley, John A},
  journal={Value in Health},
  volume={20},
  number={2},
  pages={217--223},
  year={2017},
  publisher={Elsevier}
}

@article{short2008long,
  title={Long-term effects of cancer survivorship on the employment of older workers},
  author={Short, Pamela Farley and Vasey, Joseph J and Moran, John R},
  journal={Health Services Research},
  volume={43},
  number={1p1},
  pages={193--210},
  year={2008},
  publisher={Wiley Online Library}
}

@article{skinner2018healthcare,
  title={Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study},
  author={Skinner, Karen E and Fernandes, Ancilla W and Walker, Mark S and Pavilack, Melissa and VanderWalde, Ari},
  journal={Journal of medical economics},
  volume={21},
  number={2},
  pages={192--200},
  year={2018},
  publisher={Taylor \& Francis}
}

@article{stein2018assessing,
  title={Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States},
  author={Stein, Eytan M and Yang, Min and Guerin, Annie and Gao, Wei and Galebach, Philip and Xiang, Cheryl Q and Bhattacharyya, Subrata and Bonifacio, Gaetano and Joseph, George J},
  journal={Health and quality of life outcomes},
  volume={16},
  number={1},
  pages={193},
  year={2018},
  publisher={BioMed Central}
}

@misc{team2014r,
  title={R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2013},
  author="{R Core Team}",
  year={2014}
}

@article{thokala2016multiple,
  title={Multiple criteria decision analysis for health care decision making-an introduction: report 1 of the ISPOR MCDA Emerging Good Practices Task Force},
  author={Thokala, Praveen and Devlin, Nancy and Marsh, Kevin and Baltussen, Rob and Boysen, Meindert and Kalo, Zoltan and Longrenn, Thomas and Mussen, Filip and Peacock, Stuart and Watkins, John and others},
  journal={Value in health},
  volume={19},
  number={1},
  pages={1--13},
  year={2016},
  publisher={Elsevier}
}


@article{van1994costs,
  title={Costs, effects and C/E-ratios alongside a clinical trial},
  author={Van Hout, Ben A and Al, Maiwenn J and Gordon, Gilad S and Rutten, Frans FH},
  journal={Health economics},
  volume={3},
  number={5},
  pages={309--319},
  year={1994},
  publisher={Wiley Online Library}
}

@article{wong2018assessment,
  title={Assessment of costs associated with adverse events in patients with cancer},
  author={Wong, William and Yim, Yeun Mi and Kim, Ashley and Cloutier, Martin and Gauthier-Loiselle, Marjolaine and Gagnon-Sanschagrin, Patrick and Guerin, Annie},
  journal={PloS one},
  volume={13},
  number={4},
  pages={e0196007},
  year={2018},
  publisher={Public Library of Science}
}

@article{woods2017nice,
  title={NICE DSU TECHNICAL SUPPORT DOCUMENT 19: PARTITIONED SURVIVAL ANALYSIS FOR DECISION MODELLING IN},
  author={Woods, Beth and Sideris, Eleftherios and Palmer, Stephen and Latimer, Nick and Soares, Marta},
  year={2017}
}


@article{soria2018osimertinib,
  title={Osimertinib in untreated EGFR-mutated advanced non--small-cell lung cancer},
  author={Soria, Jean-Charles and Ohe, Yuichiro and Vansteenkiste, Johan and Reungwetwattana, Thanyanan and Chewaskulyong, Busyamas and Lee, Ki Hyeong and Dechaphunkul, Arunee and Imamura, Fumio and Nogami, Naoyuki and Kurata, Takayasu and others},
  journal={New England journal of medicine},
  volume={378},
  number={2},
  pages={113--125},
  year={2018},
  publisher={Mass Medical Soc}
}


@article{wu2017dacomitinib,
  title={Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial},
  author={Wu, Yi-Long and Cheng, Ying and Zhou, Xiangdong and Lee, Ki Hyeong and Nakagawa, Kazuhiko and Niho, Seiji and Tsuji, Fumito and Linke, Rolf and Rosell, Rafael and Corral, Jesus and others},
  journal={The Lancet Oncology},
  volume={18},
  number={11},
  pages={1454--1466},
  year={2017},
  publisher={Elsevier}
}

@article{mok2018improvement,
  title={Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non--Small-Cell Lung Cancer and EGFR-Activating Mutations},
  author={Mok, Tony S and Cheng, Ying and Zhou, Xiangdong and Lee, Ki Hyeong and Nakagawa, Kazuhiko and Niho, Seiji and Lee, Min and Linke, Rolf and Rosell, Rafael and Corral, Jesus and others},
  journal={Journal of Clinical Oncology},
  pages={JCO--2018},
  year={2018},
  publisher={American Society of Clinical Oncology}
}

@article{park2016afatinib,
  title={Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial},
  author={Park, Keunchil and Tan, Eng-Huat and O'Byrne, Ken and Zhang, Li and Boyer, Michael and Mok, Tony and Hirsh, Vera and Yang, James Chih-Hsin and Lee, Ki Hyeong and Lu, Shun and others},
  journal={the Lancet oncology},
  volume={17},
  number={5},
  pages={577--589},
  year={2016},
  publisher={Elsevier}
}

@article{paz2017afatinib,
  title={Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial},
  author={Paz-Ares, L and Tan, E-H and Oâ€™byrne, K and Zhang, L and Hirsh, V and Boyer, M and Yang, JC-H and Mok, T and Lee, KH and Lu, S and others},
  journal={Annals of Oncology},
  volume={28},
  number={2},
  pages={270--277},
  year={2017},
  publisher={Oxford University Press}
}


@article{sequist2013phase,
  title={Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations},
  author={Sequist, Lecia V and Yang, James Chih-Hsin and Yamamoto, Nobuyuki and O'Byrne, Kenneth and Hirsh, Vera and Mok, Tony and Geater, Sarayut Lucien and Orlov, Sergey and Tsai, Chun-Ming and Boyer, Michael and others},
  journal={Journal of clinical oncology},
  volume={31},
  number={27},
  pages={3327--3334},
  year={2013},
  publisher={American Society of Clinical Oncology}
}


@article{yang2015afatinib,
  title={Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials},
  author={Yang, James Chih-Hsin and Wu, Yi-Long and Schuler, Martin and Sebastian, Martin and Popat, Sanjay and Yamamoto, Nobuyuki and Zhou, Caicun and Hu, Cheng-Ping and O'Byrne, Kenneth and Feng, Jifeng and others},
  journal={The lancet oncology},
  volume={16},
  number={2},
  pages={141--151},
  year={2015},
  publisher={Elsevier}
}

@article{wu2014afatinib,
  title={Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial},
  author={Wu, Yi-Long and Zhou, Caicun and Hu, Cheng-Ping and Feng, Jifeng and Lu, Shun and Huang, Yunchao and Li, Wei and Hou, Mei and Shi, Jian Hua and Lee, Kye Young and others},
  journal={The lancet oncology},
  volume={15},
  number={2},
  pages={213--222},
  year={2014},
  publisher={Elsevier}
}

@article{rosell2012erlotinib,
  title={Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial},
  author={Rosell, Rafael and Carcereny, Enric and Gervais, Radj and Vergnenegre, Alain and Massuti, Bartomeu and Felip, Enriqueta and Palmero, Ramon and Garcia-Gomez, Ramon and Pallares, Cinta and Sanchez, Jose Miguel and others},
  journal={The lancet oncology},
  volume={13},
  number={3},
  pages={239--246},
  year={2012},
  publisher={Elsevier}
}

@article{de2015erlotinib,
  title={Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial},
  author={De Marinis, Filippo and Vergnenegre, Alain and Passaro, Antonio and Dubos-Arvis, Catherine and Carcereny, Enric and Drozdowskyj, Ana and Zeaiter, Ali and Perez-Moreno, Pablo and Rosell, Rafael},
  journal={Future oncology},
  volume={11},
  number={3},
  pages={421--429},
  year={2015},
  publisher={Future Medicine}
}

@article{costa2014impact,
  title={The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial},
  author={Costa, Carlota and Molina-Vila, Miguel Angel and Drozdowskyj, Ana and Gimenez-Capitan, Anna and Bertran-Alamillo, Jordi and Karachaliou, Niki and Gervais, Radj and Massuti, Bartomeu and Wei, Jia and Moran, Teresa and others},
  journal={Clinical Cancer Research},
  pages={clincanres--2233},
  year={2014},
  publisher={AACR}
}

@article{wu2015first,
  title={First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study},
  author={Wu, Y-L and Zhou, C and Liam, C-K and Wu, G and Liu, X and Zhong, Z and Lu, S and Cheng, Y and Han, B and Chen, L and others},
  journal={Annals of oncology},
  volume={26},
  number={9},
  pages={1883--1889},
  year={2015},
  publisher={Oxford University Press}
}

@article{zhou2011erlotinib,
  title={Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study},
  author={Zhou, Caicun and Wu, Yi-Long and Chen, Gongyan and Feng, Jifeng and Liu, Xiao-Qing and Wang, Changli and Zhang, Shucai and Wang, Jie and Zhou, Songwen and Ren, Shengxiang and others},
  journal={The lancet oncology},
  volume={12},
  number={8},
  pages={735--742},
  year={2011},
  publisher={Elsevier}
}

@article{zhou2015final,
  title={Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)},
  author={Zhou, C and Wu, YL and Chen, G and Feng, J and Liu, X-Q and Wang, C and Zhang, S and Wang, J and Zhou, S and Ren, S and others},
  journal={Annals of Oncology},
  volume={26},
  number={9},
  pages={1877--1883},
  year={2015},
  publisher={Oxford University Press}
}

@article{han2012first,
  title={First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung},
  author={Han, Ji-Youn and Park, Keunchil and Kim, Sang-We and Lee, Dae Ho and Kim, Hyae Young and Kim, Heung Tae and Ahn, Myung Ju and Yun, Tak and Ahn, Jin Seok and Suh, Cheolwon and others},
  journal={Journal of clinical oncology},
  volume={30},
  number={10},
  pages={1122--1128},
  year={2012},
  publisher={American Society of Clinical Oncology}
}

@article{mitsudomi2010gefitinib,
  title={Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial},
  author={Mitsudomi, Tetsuya and Morita, Satoshi and Yatabe, Yasushi and Negoro, Shunichi and Okamoto, Isamu and Tsurutani, Junji and Seto, Takashi and Satouchi, Miyako and Tada, Hirohito and Hirashima, Tomonori and others},
  journal={The lancet oncology},
  volume={11},
  number={2},
  pages={121--128},
  year={2010},
  publisher={Elsevier}
}


@article{mok2009gefitinib,
  title={Gefitinib or carboplatin--paclitaxel in pulmonary adenocarcinoma},
  author={Mok, Tony S and Wu, Yi-Long and Thongprasert, Sumitra and Yang, Chih-Hsin and Chu, Da-Tong and Saijo, Nagahiro and Sunpaweravong, Patrapim and Han, Baohui and Margono, Benjamin and Ichinose, Yukito and others},
  journal={New England Journal of Medicine},
  volume={361},
  number={10},
  pages={947--957},
  year={2009},
  publisher={Mass Medical Soc}
}


@article{fukuoka2011biomarker,
  title={Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non--small-cell lung cancer in Asia (IPASS)},
  author={Fukuoka, Masahiro and Wu, Yi-Long and Thongprasert, Sumitra and Sunpaweravong, Patrapim and Leong, Swan-Swan and Sriuranpong, Virote and Chao, Tsu-Yi and Nakagawa, Kazuhiko and Chu, Da-Tong and Saijo, Nagahiro and others},
  journal={Journal of clinical oncology},
  volume={29},
  number={21},
  pages={2866--2874},
  year={2011},
  publisher={American Society of Clinical Oncology}
}


@article{maemondo2010gefitinib,
  title={Gefitinib or chemotherapy for non--small-cell lung cancer with mutated EGFR},
  author={Maemondo, Makoto and Inoue, Akira and Kobayashi, Kunihiko and Sugawara, Shunichi and Oizumi, Satoshi and Isobe, Hiroshi and Gemma, Akihiko and Harada, Masao and Yoshizawa, Hirohisa and Kinoshita, Ichiro and others},
  journal={New England Journal of Medicine},
  volume={362},
  number={25},
  pages={2380--2388},
  year={2010},
  publisher={Mass Medical Soc}
}


@article{inoue2012updated,
  title={Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin--paclitaxel for chemo-na{\"\i}ve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)},
  author={Inoue, A and Kobayashi, K and Maemondo, M and Sugawara, S and Oizumi, S and Isobe, H and Gemma, A and Harada, M and Yoshizawa, H and Kinoshita, I and others},
  journal={Annals of oncology},
  volume={24},
  number={1},
  pages={54--59},
  year={2012},
  publisher={Oxford University Press}
}


@article{han2017combination,
  title={Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial},
  author={Han, Baohui and Jin, Bo and Chu, Tianqing and Niu, Yanjie and Dong, Yu and Xu, Jianlin and Gu, Aiqing and Zhong, Hua and Wang, Huimin and Zhang, Xueyan and others},
  journal={International journal of cancer},
  volume={141},
  number={6},
  pages={1249--1256},
  year={2017},
  publisher={Wiley Online Library}
}


@article{yang2014first,
  title={First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial},
  author={Yang, James Chih-Hsin and Kang, Jin Hyoung and Mok, Tony and Ahn, Myung-Ju and Srimuninnimit, Vichien and Lin, Chia-Chi and Kim, Dong-Wan and Tsai, Chun-Ming and Barraclough, Helen and Altug, Sedat and others},
  journal={European Journal of Cancer},
  volume={50},
  number={13},
  pages={2219--2230},
  year={2014},
  publisher={Elsevier}
}


@article{yang2016first,
  title={First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non--Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study},
  author={Yang, James Chih-Hsin and Srimuninnimit, Vichien and Ahn, Myung-Ju and Lin, Chia-Chi and Kim, Sang-We and Tsai, Chun-Ming and Mok, Tony and Orlando, Mauro and Puri, Tarun and Wang, Xin and others},
  journal={Journal of Thoracic Oncology},
  volume={11},
  number={3},
  pages={370--379},
  year={2016},
  publisher={Elsevier}
}

@article{mok2017osimertinib,
  title={Osimertinib or platinum--pemetrexed in EGFR T790M--positive lung cancer},
  author={Mok, Tony S and Wu, Yi-Long and Ahn, Myung-Ju and Garassino, Marina C and Kim, Hye R and Ramalingam, Suresh S and Shepherd, Frances A and He, Yong and Akamatsu, Hiroaki and Theelen, Willemijn SME and others},
  journal={New England Journal of Medicine},
  volume={376},
  number={7},
  pages={629--640},
  year={2017},
  publisher={Mass Medical Soc}
}


@article{mitsudomi20171348poverall,
  title={1348POverall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies},
  author={Mitsudomi, T and Ahn, MJ and Bazhenova, L and Blackhall, F and Hida, T and Majem Tarruella, M and Vowler, SL and Laus, G and J{\"a}nne, PA and Yang, JC-H},
  journal={Annals of Oncology},
  volume={28},
  number={suppl\_5},
  year={2017},
  publisher={Oxford University Press}
}

@article{soria2015gefitinib,
  title={Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial},
  author={Soria, Jean-Charles and Wu, Yi-Long and Nakagawa, Kazuhiko and Kim, Sang-We and Yang, Jin-Ji and Ahn, Myung-Ju and Wang, Jie and Yang, James Chih-Hsin and Lu, You and Atagi, Shinji and others},
  journal={The Lancet Oncology},
  volume={16},
  number={8},
  pages={990--998},
  year={2015},
  publisher={Elsevier}
}

@article{mok2017gefitinib,
  title={Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation--positive non--small-cell lung cancer resistant to first-line gefitinib (impress): Overall survival and biomarker analyses},
  author={Mok, Tony SK and Kim, Sang-We and Wu, Yi-Long and Nakagawa, Kazuhiko and Yang, Jin-Ji and Ahn, Myung-Ju and Wang, Jie and Yang, James Chih-Hsin and Lu, You and Atagi, Shinji and others},
  journal={Journal of Clinical Oncology},
  volume={35},
  number={36},
  pages={4027--4034},
  year={2017},
  publisher={American Society of Clinical Oncology}
}

@article{yang2017phase,
  title={A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations},
  author={Yang, JJ and Zhou, Q and Yan, HH and Zhang, XC and Chen, HJ and Tu, HY and Wang, Z and Xu, CR and Su, J and Wang, BC and others},
  journal={British journal of cancer},
  volume={116},
  number={5},
  pages={568},
  year={2017},
  publisher={Nature Publishing Group}
}

@article{yu2014phase,
  title={A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer},
  author={Yu, Hui and Zhang, Jian and Wu, Xianghua and Luo, Zhiguo and Wang, Huijie and Sun, Si and Peng, Wei and Qiao, Jie and Feng, Yu and Wang, Jialei and others},
  journal={Cancer biology \& therapy},
  volume={15},
  number={7},
  pages={832--839},
  year={2014},
  publisher={Taylor \& Francis}
}

